These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 18350737)

  • 21. Orlistat increases serum paraoxonase activity in obese patients.
    Audikovszky M; Pados G; Seres I; Harangi M; Fülöp P; Katona E; Illyés L; Winkler G; Katona EM; Paragh G
    Nutr Metab Cardiovasc Dis; 2007 May; 17(4):268-73. PubMed ID: 17134960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K; Finer N; Rössner S
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial].
    Toubro S; Hansen DL; Hilsted JC; Porsborg PA; Astrup AV;
    Ugeskr Laeger; 2001 May; 163(21):2935-40. PubMed ID: 11402974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
    Sabuncu T; Ucar E; Birden F; Yasar O
    Diabetes Nutr Metab; 2004 Apr; 17(2):103-7. PubMed ID: 15244102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.
    Pathan MF; Latif ZA; Nazneen NE; Mili SU
    Bangladesh Med Res Counc Bull; 2004 Apr; 30(1):1-8. PubMed ID: 15376463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of weight loss drugs on obesity and cardiovascular risk factors in obese adolescents: a meta-analysis of randomized controlled trials.
    Czernichow S; Lee CM; Barzi F; Greenfield JR; Baur LA; Chalmers J; Woodward M; Huxley RR
    Obes Rev; 2010 Feb; 11(2):150-8. PubMed ID: 19573052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J; Lippl F; Klose G; Schusdziarra V
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of orlistat on obesity-related diseases - a six-month randomized trial.
    Guy-Grand B; Drouin P; Eschwège E; Gin H; Joubert JM; Valensi P
    Diabetes Obes Metab; 2004 Sep; 6(5):375-83. PubMed ID: 15287931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N; Ryan DH; Renz CL; Hewkin AC
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.